

First Name: Nobuko  
Last Name: Hijiya  
Institution: Lurie Children's Hospital of Chicago - Northwestern University  
Address 1: 225 E Chicago Ave.  
Address 2: Box #30  
City: Chicago  
State/Province: IL  
Country: USA  
Zip: 60611  
Phone: 312-227-4090  
Alternate Phone: 312-227-4000  
Email: [nhijiya@luriechildrens.org](mailto:nhijiya@luriechildrens.org)

---

Requirements to submit AOI:

---

A comprehensive review of previously published data has been completed.: Yes  
The specific aims are clear and focused.: Yes  
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.: Yes  
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

---

Project Title: Long-term morbidity in survivors of childhood CML  
Planned research population (eligibility criteria): Survivors of CML (76 patients from the original cohort and 72 patients from the expansion cohort)  
Proposed specific aims: 1) Quantify the incidence of late effects in childhood CML survivors 2) Evaluate the risk factors for morbidities in survivors of childhood CML 3) Compare morbidity in childhood CML survivors between the original and expansion cohorts 4) Compare morbidity in childhood CML survivors with the general survivor population  
Will the project require non-CCSS funding to complete?: No  
If yes, what would be the anticipated source(s) and timeline(s) for securing funding?:

---

Does this project require contact of CCSS study subjects for . . .

---

Additional self-reported information: No  
Biological Samples: No  
Medical record data: No  
If yes to any of the above, please briefly describe.:

---

What CCSS Working Group(s) would likely be involved? (Check all that apply)

---

Second Malignancy:  
Chronic Disease: Primary  
Psychology / Neuropsychology:

Genetics:  
Cancer Control:  
Epidemiology / Biostatistics:

---

To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as outcome (primary or secondary) or correlative factors. (Check all that apply)

---

Late mortality: Primary  
Second Malignancy: Primary

---

#### Health Behaviors

---

Tobacco: Secondary  
Alcohol: Secondary  
Physical activity: Secondary  
Medical screening: Secondary  
Other:  
If other, please specify:

---

#### Psychosocial

---

Insurance: Secondary  
Marriage: Secondary  
Education: Secondary  
Employment: Secondary  
Other:  
If other, please specify:

---

#### Medical conditions

---

Hearing/Vision/Speech: Primary  
Hormonal systems: Primary  
Heart and vascular: Primary  
Respiratory: Primary  
Digestive: Primary  
Surgical procedures: Primary  
Brain and nervous system: Primary  
Other:  
If other, please specify:

---

#### Medications

---

Describe medications:

---

---

Pregnancy and offspring: Primary  
Family History: Secondary

---

Psychologic/Quality of Life

---

BSI-18: Secondary  
SF-36: Secondary  
CCSS-NCQ: Secondary  
PTS: Secondary  
PTG: Secondary  
Other:  
If other, please specify:

---

Chronic conditions (CTCAE v3):  
Health status:

---

Demographic

---

Age: Primary  
Race: Primary  
Sex: Primary  
Others:  
If others, please specify:

---

Cancer treatment

---

Chemotherapy: Correlative Factors  
Radiation therapy: Correlative Factors  
Surgery:

---

Anticipated sources of statistical support

---

CCSS Statistical Center: Yes  
Local institutional statistician:  
If local, please provide the name(s) and contact information of the statistician(s) to be involved.:  
Will this project utilize CCSS biologic samples?: No

---

If yes, which of the following?

---

Buccal cell DNA:  
Peripheral blood:  
Lymphoblastoid cell lines:  
Second malignancy pathology samples:

Other requiring collection of samples:  
If other, please explain:

---

---

Other general comments: We acknowledge the population is small, but there are very few studies that reported long-term morbidity in children with CML. The proposed study will add valuable information. The plan was discussed with Dr Kiri Ness.